Veracyte Announces that Findings Published in JCO Precision Oncology Suggest Potential of Decipher GRID-Derived Gene Signatures to Predict Treatment Response in Recurrent Prostate Cancer
22 Agosto 2023 - 9:15AM
Business Wire
New data are from a retrospective analysis of
the Phase 2 STREAM trial
Veracyte, Inc. (Nasdaq: VCYT) announced that new data published
in JCO Precision Oncology suggest that gene expression signatures
derived from the company’s Decipher Genomics Resource for
Intelligent Discovery (GRID) database may help advance
understanding of the genomic drivers impacting patient response to
treatment for recurrent prostate cancer. The findings, from the
Phase 2 STREAM study, suggest the potential to use transcriptomic
signatures to identify patients in this setting who may benefit
from more intensive salvage therapy as well as those who may need
alternative care such as chemotherapy.
“The STREAM study showed that, despite treatment with six months
of androgen deprivation therapy and enzalutamide, nearly 50% of
patients receiving radiation therapy for prostate cancer that has
returned experience relapse within three years,” said Andrew
Armstrong, M.D., ScM, professor of Medicine and director of
Research, Duke Cancer Institute Center for Prostate and Urologic
Cancers, and senior/corresponding author for the manuscript. “Using
the Decipher GRID database, we found that men in the STREAM study
with luminal differentiated genotypes had excellent outcomes, while
those whose tumors had a basal, luminal proliferating genotype or
other specific genomic characteristics such as PTEN loss had a
higher risk of recurrence despite these therapies.”
The three-center, prospective Phase 2 STREAM study was led by
Dr. Armstrong and Duke University colleague Rhonda L. Bitting, M.D.
The trial evaluated the safety and efficacy of adding six months of
enzalutamide to androgen deprivation therapy (ADT) and salvage
radiotherapy in patients with rising prostate-specific antigen
(PSA) following radical prostatectomy and radiotherapy (RT). A
previous publication demonstrated that 51% of men remained free of
disease at three years following treatment.
Using prostatectomy tissue from 31 study participants, all of
whom had NCCN intermediate- (12.9%) or high-risk (87.1%) disease,
researchers conducted a retrospective analysis using the Decipher
GRID database to determine whether specific genomic signatures
could help predict which patients would benefit from the aggressive
therapy regimen, and which may require additional or alternative
care.
Results suggest that patients in the study who experienced
shorter progression-free survival (PFS) over three years had a
luminal proliferating tumor subtype, loss of the PTEN gene and/or
higher homologous recombination deficiency (HRD) signature scores.
Patients with luminal differentiated or luminal A-type tumors
and/or higher postoperative ADT responsiveness genomic signature
scores were more likely to have durable responses and long-term
remissions with the aggressive systemic regimen of ADT and
enzalutamide combined with salvage radiotherapy.
“This study provides further evidence that the Decipher GRID
database is a valuable tool to help researchers better understand
the specific genomic signatures and factors that impact prostate
cancer disease progression and individual responses to various
treatment approaches,” said Elai Davicioni, Ph.D., Veracyte’s
medical director for Urology.
The Decipher GRID database includes more than 100,000
whole-transcriptome profiles from patients with urologic cancers
and is used by Veracyte and its partners to contribute to continued
research and help advance understanding of prostate and other
urologic cancers. GRID-derived information is available on a
Research Use Only basis.
About Veracyte
Veracyte (Nasdaq: VCYT) is a global diagnostics company whose
vision is to transform cancer care for patients all over the world.
We empower clinicians with the high-value insights they need to
guide and assure patients at pivotal moments in the race to
diagnose and treat cancer. Our high-performing tests enable
clinicians to make more confident diagnostic, prognostic, and
treatment decisions for some of the most challenging diseases such
as thyroid, prostate, breast, bladder and lung cancers, as well as
interstitial lung diseases. We help patients avoid unnecessary
procedures and speed time to diagnosis and appropriate treatment.
In addition to making our tests available in the U.S. through our
central laboratories, we also aim to deliver our tests to patients
worldwide through a distributed model to laboratories that can
perform them locally. Veracyte is based in South San Francisco,
California. For more information, please visit www.veracyte.com and
follow the company on Twitter (@veracyte).
Cautionary Note Regarding Forward-Looking Statements
This press release contains forward-looking statements,
including, but not limited to our statements related to our plans,
objectives, expectations (financial and otherwise) or intentions
with respect to our clinical tests in and outside of the United
States. Forward-looking statements can be identified by words such
as: “appears,” "anticipate," "intend," "plan," "expect," "believe,"
"should," "may," "will," “positioned,” “designed” and similar
references to future periods. Examples of forward-looking
statements include, among others, that the Decipher GRID database
may help advance understanding of the genomic drivers impacting
patients’ response to treatment for recurrent prostate cancer, and
that it may ultimately help inform more personalized treatment for
patients with recurrent disease. Additional factors that may impact
these forward-looking statements can be found under the caption
“Risk Factors” in our Annual Report on Form 10-K filed on February
22, 2023, and our Quarterly Report on Form 10-Q filed for the three
months ended August 9, 2023. Copies of these documents, when
available, may be found in the Investors section of our website at
https://investor.veracyte.com. These forward-looking statements
speak only as of the date hereof and, except as required by law, we
specifically disclaim any obligation to update these
forward-looking statements or reasons why actual results might
differ, whether as a result of new information, future events or
otherwise.
Decipher Prostate is available in the US as part of Veracyte’s
CLIA-validated laboratory developed test (LDT) service. This test
has not been cleared or approved by the FDA. The Decipher GRID
database is For Research Use Only - Not for use in diagnostic
procedures / Not for use to support treatment decision.
Veracyte, the Veracyte logo and Decipher are registered
trademarks of Veracyte, Inc. and its subsidiaries in the U.S. and
selected countries.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20230822976286/en/
Investors: investors@veracyte.com 619-393-1545
Media: Tracy Morris VP of Global Corporate Communications
tracy.morris@veracyte.com 650-380-4413
Veracyte (NASDAQ:VCYT)
Gráfico Histórico do Ativo
De Mai 2024 até Jun 2024
Veracyte (NASDAQ:VCYT)
Gráfico Histórico do Ativo
De Jun 2023 até Jun 2024